PRESENTATION FOR IMMEDIATE RELEASE 24 MARCH 2010 Pharmaceutical and Healthcare group, Stirling Products Limited (ASX:STI) is pleased to advise the Company will be presenting at the Proactive Investors “Ultimate Healthcare & Biotechnology Event 2010” at the Sydney Harbour Marriott later today. See: proactiveinvestors.com.au The Company’s current Broker Presentation, as revised today, forms part of this Company Announcement and follows. For further information see www.stirlingproducts.net – or contact: Peter Boonen Managing Director Stirling Products Limited Ph: +61 2 9299 9270 E: peter.boonen@stirlingproducts.net For all Investor Relations inquiries please contact: James Moses Mandate Corporate Ph: +61 420 991 574 E: james@mandatecorporate.com.au

For

per

sona

l use

onl

y

Ultimate HealthcareUltimate Healthcare & Biotechnology Event 2010

Presentation at Sydney

gyy y

Harbour Marriott24 March 201024 March 2010F

or p

erso

nal u

se o

nly

Forward Moving Statements

This presentation provides only an overview of Stirling Products Limited ABN 32 077 105 429 p p y g(ASX:STI) and its opportunities. The information may require further explanation and/or clarification. Accordingly, this information should not be relied upon independently and should be considered in conjunction with past and future public information and announcements that are made by STI. Please contact STI and/or refer to the Company's website for further information.

The views expressed in this presentation may contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs aboutwhich may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside STI’s control. These factors could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation. Because actual results may differ materially to assumptions made and STI’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with cautionpresentation with caution.

Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

For

per

sona

l use

onl

y

About Stirling Products LimitedASX:STI

g

In only 12 months – Stirling has built a global pharmaceutical and healthcare company that now has:

l i f di i i• sales commencing across four divisions

• a freehold high-tech $20M+ manufacturing plant in Canada and its future freehold 450 sq m Sydney office HQ

• a board with proven global senior industry experience and expertiseand a team of world-class managers & scientists

• a proven top-class National pharma sales force in place in Australia

• extensive IP and product range

• announced relationship with Cipla – major global generics manufacturer

• three serious blockbuster realization opportunitiesFor

per

sona

l use

onl

y

2010-2011 Full YearPositioned for:

• ‘Stirling Pharma’ manufacturing base in Canada - commencing Q2

Sales – Building our Business Units

• ‘Stirling Health’ Australian pharmacy brand launched at APP in March 2010

• ‘Natures Firewall’ to be launched in Q2, 2010 as an Internet based brand

• ‘i Naturals’ to be launched in Q4 2010 as a Network Marketing brand• i-Naturals to be launched in Q4, 2010 as a Network Marketing brand

Blockbuster Realization – Building our Futureg• leveraging drug delivery platform to gain exclusivity over suite of drugs

• treatment of AIDS, TB and Flu

• obesity candidate – targeting JV with major pharma by end 2011For

per

sona

l use

onl

y

Corporate – Our Boardp• Directors

Peter Boonen Managing Director

Neil Covey Director

G lshan J groo CFO/DirectorGulshan Jugroo CFO/Director

Professor Glyn Tonge Non Executive Director

• The Company’s corporate headquarters are in Sydney, Australia

• North American operations are based in Prince Edward Island, Canada

• Manufacturing operations are based at Cape Breton, Canada

• South African joint venture (Stanimate) based in Johannesburg

For

per

sona

l use

onl

y

Scientific & Management Expertise

Neil Covey – Extensive industry expertise. Former sales and marketing manager for Bayer Australiamanager for Bayer Australia

Prof Glyn Tonge – Extensive industry experience. Pharma, corporate finance, funds manager, funder, M&A, corporate and governance

Michael Elliott E tensi e National Sales Management e perience ith Pfi erMichael Elliott – Extensive National Sales Management experience with Pfizer and Innovex

Dr Allen Bain – pharmacologist who co-developed a block buster anti-arrhythmia drug now being commercialized by Merckarrhythmia drug now being commercialized by Merck

Dr Aldar Bourinbaiar – specialist in viral disease, discovered an AIDS treatment used globally

Dr Galyna Kutsyna – a researcher and specialist in AIDS and viral disease

Dr Manuel Carpio – CEO Canada, Doctor of Veterinary Medicine

Dr Hinner Koster – specialist in animal nutrition and healthDr Hinner Koster specialist in animal nutrition and health

Dr Hugo Hattingh – specialist in animal nutrition and health

For

per

sona

l use

onl

y

Manufacturing Facility

Stirling’s 4,310sqm $20M+ Pharmaceutical Plant

g y

Stirling s 4,310sqm $20M Pharmaceutical Plant

For

per

sona

l use

onl

y

Manufacturing Facility

Stirling’s 4,310sqm $20M+ Pharmaceutical Plant

g y

Stirling s 4,310sqm $20M Pharmaceutical Plant

laboratorylaboratoryFor

per

sona

l use

onl

y

Manufacturing Facilityg y

With current fit-out and configuration the plant has an annual capacity to manufacture and package over 550 million tablets, 5 million bottles p gand blend up to 1.5 million kg of product.F

or p

erso

nal u

se o

nly

First Products to MarketStirling products being launched in markets include:

Stirling Health – Pharmacy Sales Division (launched at APP2010)A growing range of OTC, generic, health and beauty products, including

products marketed for third partiesproducts marketed for third parties

Stirling Pharma – Contract manufacturing services

Botanical Dietary Supplements – ‘Nature’s Firewall’ & ‘i-Naturals’a range of 26 unique products

I d l t d/ dj t t t t I X l bj t tImmunomodulator and/or adjuvant treatment - ImmunoXel subject to reg approval– for all strains of TB, TB/HIV co-infection, AIDS and influenza

For

per

sona

l use

onl

y

Products in DevelopmentStirling has three fully developed products having blockbuster – company making

p

potential and which are the subject of ongoing commercialization works:

• ImmunoXel – as an immunomodulator for treatment of AIDS, TB and flu

• Inhalation Drug Delivery Platform – proven and patented technology with demonstrated capability of improved delivery of many drugs through natural inhalation pro ides Stirling the potential and opport nit of sec ringinhalation – provides Stirling the potential and opportunity of securing market share in a range of blockbuster drugs as they come off patent

• R-Salbutamol – world’s only single enantiomer beta agonist patented for• R-Salbutamol – world s only single enantiomer beta agonist patented forhuman obesity – trial in beagle dogs demonstrated an approximate 2% per week weight loss

For

per

sona

l use

onl

y

Drug Delivery PlatformKey Features

g y

• Technology fully proven, developed and patented

• Drug transport velocity - matched to the patient’s natural breathing

L d iti d d li th• Less deposition on drug delivery pathways

• Up to 3 times the aerosol concentration of other ultrasonic devices

• Delivered drugs – sub 5 micron - have much better & faster absorptiong p

• Active drug is in unique disposable capsules – competition protection

• Testing has shown substantively LESS active drug (than oral) is needed to provide the same benefit potential for increased safety and less side effectsprovide the same benefit – potential for increased safety and less side effects

• Can potentially be used for administration of many major drugs

• Design and manufacture of pre-production devices underway

For

per

sona

l use

onl

y

Botanical Products

Why a Focus on Botanicals?Why a Focus on Botanicals?

• The market for herbal and botanical products is forecast to grow by overThe market for herbal and botanical products is forecast to grow by over 168% over the next 5 years to over US$33 billion

• Over 60% of all New Chemical Entities for prescription pharmaceuticalsin the last 5 years have been derived from natural or synthesized naturalin the last 5 years have been derived from natural or synthesized natural sources

• There is a race on for the development of all natural immunomodulators

For

per

sona

l use

onl

y

ImmunoXel

ImmunomodulatorImmunoXel has demonstrated in all its clinical trials that it:

i f l i d l t d dj t

Immunomodulator

• is a powerful immunomodulator and adjuvant• substantively tunes the Immune System• enhances efficacy of - antibiotics, viral therapies and chemotherapies• can substantially shorten drug and chemotherapy treatment durationy g py• can reduce and reverse treatment toxicity side-effects – esp. in liver and

kidneys• is market ready for treatment of TB, TB/HIV, AIDS

over 800 patients treated in clinical trials• over 800 patients treated in clinical trials – mainly TB, TB/HIV but also AIDS and influenza

• is a blockbuster product candidate

For

per

sona

l use

onl

y

Proven in Tuberculosis

ImmunoXel• Enhances efficacy of drugs 2-10 fold• Shortens therapy duration 3-12 fold

R d d t i it f

ImmunoXel

• Reduces and reverses toxicity of current TB drugs

• Is market ready for TB and TB/HIV treatment

• Over 800 patients treated in clinical trials to date

“…a drug effective against drug resistant TB can earn US$300 million a year…”y

- Global TB AllianceFor

per

sona

l use

onl

y

Proven in AIDS Trials

ImmunoXelIn clinical trials when ImmunoXel was used as an adjuvant to anti-retroviral (ART)

chemotherapy in the treatment of AIDS patients and compared to patients only on ART I X l

ImmunoXel

ART - ImmunoXel:

• Significantly increased CD3 T-lymphocytesCD 4 T ll l ti l t d bl d• CD-4 T cell population almost doubled

• The CD-4/CD-8 ratio increased 29.7%• CD-20 and B-lymphocytes declined to normal levels of around 333• CD-3, HLA-DR and T-cell population increased 216%p p• The CD3, CD16, CD56 and natural killer cells increased by 52.7%• 95% of all patients had decrease in viral load burden• Reduced and reversed toxicity side effects of ART• Is market ready for use as an AIDS ART adjuvant treatment• Is market ready for use as an AIDS ART adjuvant treatment

Over 35 million people are living with HIV/AIDS today

For

per

sona

l use

onl

y

Botanical ProductsBOTANICAL PRODUCTS AS DIETARY SUPPLEMENTS

Condition ProductAllergies ALLERGIL

DIETARY SUPPLEMENTS

Stirling has joint ventured the exclusive global marketing rights to a range of 26 botanical

Anemia ANEMINArthritis ARTROSANSore muscles ARTROSAN-SPORTAsthma BRONCHINCholesterol CHOLENORMHeart health CORDEVITto a range of 26 botanical

products that until now have only been sold through health care professionals in limited

Heart health CORDEVITHypertension CRYSTALDiabetes and obesity DIABETINImmune system IMMUNOXELImmune system – preventative IMMUNOXEL-PHormonal imbalance in women FЕМINAL

parts of Europe

Each product has potential health benefits and has been

Allergy and autoimmune diseases LIZORMMuscle support MYOTROPKidney diseases NEPHROPATHINNeurological diseases NEURINGastritis, stomach ulcer NORKCh i titi & i di ti PANCRENtested and proven through

extensive clinical trials in major academic and research institutions and also proven

Chronic pancreatitis & indigestion PANCRENChronic prostatitis PREDZARENVaricose veins PROVENIndigestion RENORMRheumatism, arthritis RHEUMOSANThyroid gland dysfunction SCHIZARENinstitutions and also proven

through their extensive use in Eastern Europe

Thyroid gland dysfunction SCHIZARENHepatitis SVITANOKEndocrine disorders TROPONORMPsycho-emotional stress ZSP

For

per

sona

l use

onl

y

Development

ST-810 for Obesity

p

ST- 810 is fully developed, chirally (molecular) pure, and has been safely used by humans for respiratory disease (asthma) for over 15 years in its purified form and 30 years in its original formulation

ST 810 for Obesity

30 years in its original formulation.

Stirling is re-purposing this “old drug” for a “new use” - a well established product development process within the pharmaceutical industry.

ST- 810 is a “metabolic switch” that turns off the body’s fat production receptors and then lets the body naturally adjust its weight.

To commercialize the ST- 810 product, the Company intends to partner with a major pharmaceutical group and aims to achieve this by 2011 year end.

For

per

sona

l use

onl

y

Major Opportunity

Obesity

j pp y

In Australia - the total cost of obesity in 2008 was $58.2 billion which included the attributable cost of diseases such as diabetes,

Obesity

cardiovascular disease, various types of cancer and osteoarthritis.- Weighing it Up: Obesity in Australia May 2009 • House of Representatives Standing Committee Report on Health and Ageing

In USA - “It's no secret that Americans are fat… Nearly one-third of U.S. adults are overweight, and another third are technically obese, as defined by a BMI (body-mass index) of more than 30. And Americans y ( y ) 30aren't happy about it.

Last year, they spent an estimated $46 Billion on diet products.”F b M i- Forbes MagazineF

or p

erso

nal u

se o

nly

CommercializationStirling Growth Strategy• ‘Stirling Pharma’ starts manufacturing in Q2

• Launch of ‘Stirling Health’ – sales to pharmacies commence April Q2

g gy

• Launch of ‘Nature’s Firewall’ – Internet sales network based in Canada to launch in Q2

• Launch of ‘i-Naturals’ – USA based network marketing health, beauty and anti-aging products to launch in Q4 or Q1, 2011

• Licensing of products, in and out - ongoing

• Joint venturing of products and/or technologies - ongoingJoint venturing of products and/or technologies ongoing

• Relationship establishment with governments and continued clinical trials in areas of unmet need such as TB and HIV throughout the Africa – ongoing

Development of pre production inhalation platform devices ongoing• Development of pre-production inhalation platform devices - ongoingFor

per

sona

l use

onl

y

Our FutureUnderpinned by Tangible Assets• $20M+ replacement value - near new, freehold pharmaceutical plant• Freehold offices – est. value $2.5 million

…. positioned for:…. positioned for:

• sales revenues – commencing early Q2• realization of major blockbuster potential opportunities

ImmunoXel as a treatment adjunct for AIDS and TB- ImmunoXel as a treatment adjunct for AIDS and TB- inhalation drug delivery platform- obesity drug candidate

• joint ventures with major pharmasj j p• continued aggressive growth

.... to realize:

• market awarenessmarket awareness• re-assessment as an investment opportunity!

For

per

sona

l use

onl

y

Th kThank youPlease visit: stirlingproducts.net

For

per

sona

l use

onl

y